GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Haisco Pharmaceutical Group Co Ltd (SZSE:002653) » Definitions » Debt-to-Equity

Haisco Pharmaceutical Group Co (SZSE:002653) Debt-to-Equity : 0.50 (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Haisco Pharmaceutical Group Co Debt-to-Equity?

Haisco Pharmaceutical Group Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥902 Mil. Haisco Pharmaceutical Group Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ¥1,171 Mil. Haisco Pharmaceutical Group Co's Total Stockholders Equity for the quarter that ended in Sep. 2024 was ¥4,192 Mil. Haisco Pharmaceutical Group Co's debt to equity for the quarter that ended in Sep. 2024 was 0.49.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Haisco Pharmaceutical Group Co's Debt-to-Equity or its related term are showing as below:

SZSE:002653' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18   Med: 0.44   Max: 0.72
Current: 0.5

During the past 13 years, the highest Debt-to-Equity Ratio of Haisco Pharmaceutical Group Co was 0.72. The lowest was 0.18. And the median was 0.44.

SZSE:002653's Debt-to-Equity is ranked worse than
75.22% of 1013 companies
in the Biotechnology industry
Industry Median: 0.15 vs SZSE:002653: 0.50

Haisco Pharmaceutical Group Co Debt-to-Equity Historical Data

The historical data trend for Haisco Pharmaceutical Group Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haisco Pharmaceutical Group Co Debt-to-Equity Chart

Haisco Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.38 0.44 0.69 0.43

Haisco Pharmaceutical Group Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.43 0.47 0.43 0.50

Competitive Comparison of Haisco Pharmaceutical Group Co's Debt-to-Equity

For the Biotechnology subindustry, Haisco Pharmaceutical Group Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haisco Pharmaceutical Group Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Haisco Pharmaceutical Group Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Haisco Pharmaceutical Group Co's Debt-to-Equity falls into.



Haisco Pharmaceutical Group Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Haisco Pharmaceutical Group Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Haisco Pharmaceutical Group Co's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haisco Pharmaceutical Group Co  (SZSE:002653) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Haisco Pharmaceutical Group Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Haisco Pharmaceutical Group Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Haisco Pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
No. 17, Sanxiang Avenue, Shannan District, Tibet Autonomous Region, Zetang, CHN, 856000
Haisco Pharmaceutical Group Co Ltd is a pharmaceutical company based in China. It is mainly engaged in the research, development, manufacture, and sale of drugs for liver disease. Its product portfolio includes parenteral nutrition drugs, antibiotics, anesthetic agents, digestive system drugs and tumour adjuvant drug series. The company's products are being used in first rank hospitals in China.
Executives
Fan Xiu Lian Directors, executives
Zheng Wei Directors, executives
Wang Meng Secretary Dong
Wang Jun Min Directors, executives
Deng Xiang Directors, executives
Liu Han Bing Supervisors
Zhang Xiao Xu Supervisors
Tan Hong Executives
Shen Ping Director
Liang Yong Supervisors
Chen Long Independent director
Duan Qing Liang Supervisors

Haisco Pharmaceutical Group Co Headlines

No Headlines